Results 71 to 80 of about 1,279,543 (154)

Metabolic Syndrome and Pharmacological Interventions in Clinical Development

Diabetology
Metabolic syndrome prevalence is between 24 and 27% and poses a significant risk for the development of atherosclerotic cardiovascular disease (ASCVD), type 2 diabetes (T2D), or other comorbidities. Currently, no drugs are approved for metabolic syndrome
Eugen Javor, David Šarčević, Arnes Rešić   +2 more
doaj   +1 more source

Narrative literature review of antidiabetic drugs’ effect on hyperuricemia: elaborating actual data and mechanisms

Endocrine Connections
To optimize the treatment plan for patients with type 2 diabetes mellitus (T2DM) and hyperuricemia, this narrative literature review summarizes the effect of antidiabetic drugs on serum uric acid (SUA) levels using data from observational studies ...
Zhenyu Liu, Huixi Kong, Baoyu Zhang
doaj   +1 more source

Adjunctive therapy for glucose control in patients with type 1 diabetes

Diabetes, Metabolic Syndrome and Obesity, 2018
Kira Harris,1,2 Cassie Boland,1,3 Lisa Meade,1,4 Dawn Battise1,5 1Pharmacy Practice Faculty, Wingate University School of Pharmacy, Wingate, NC, USA; 2Clinical Pharmacy Specialist – Novant Health Family Medicine Residency Program, Cornelius, NC ...
Harris K, Boland C, Meade L, Battise D
doaj  

SURPASS‐CVOT and the Emerging Biology of Cardiometabolic Benefit

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8753-8756, October 2026.
Salvatore Corrao, Francesco Cosentino, Massimo Federici   +2 more
wiley   +1 more source

Fibril formation and toxicity of the non-amyloidogenic rat amylin peptide

, 2013
Full-length native rat amylin 1-37 has previously been widely shown to be unable to form fibrils and to lack the toxicity of the human amylin form leading to its use as a non-amyloidogenic control peptide.
Harris, J.R., Milton, N.G.N.
core   +1 more source

Drugs for diabetes: part 6 GLP-1 receptor agonists

, 2011
The glucagon-like peptide-1 (GLP-1) receptor agonists are a new class of injected drugs for the treatment of type 2 diabetes. They mimic the action of GLP-1 and increase the incretin effect in patients with type 2 diabetes, stimulating the release of ...
Fisher, Miles, McKay, Gerard A., McDougall, Claire   +2 more
core  

Benzodiazepine receptors and the control of ingestive behaviour in the rat [PDF]

, 1996
When administered systemically, benzodiazepine receptor agonists have been shown to increase food intake in a number of species. Conversely, benzodiazepine receptor inverse agonists bring about reliable decreases in feeding.
Higgs, Suzanne, Higgs, S
core  

Dopamine receptor subtypes and ingestive behaviour [PDF]

, 1999
Both centrally and systemically administered dopamine agonists and antagonists decrease ingestive behaviour. The aim of this thesis was to examine whether drugs acting at different receptor subtypes decreased intake in different ways.
Genn, Rachel F., Genn, R.F.
core  

Mitochondrial Adaptations in Skeletal Muscle Following Incretin‐Based Therapies: In Vitro

Journal of Cachexia, Sarcopenia and Muscle
Background Incretin‐based therapies such as glucagon‐like peptide‐1 receptor agonists (GLP‐1Ras), dual GLP‐1/GIP agonists and amylin analogues have demonstrated significant weight loss benefits.
Victoria Old, Melanie Davies, Matthew Denniff, Pratik Choudhary, Nicholas Eastley, Robert U. Ashford, Emma Watson   +6 more
doaj   +1 more source

Amylin: Pharmacology, Physiology, and Clinical Potential [PDF]

, 2015
Amylin is a pancreatic β-cell hormone that produces effects in several different organ systems. Here, we review the literature in rodents and in humans on amylin research since its discovery as a hormone about 25 years ago.
Roth, Jonathan D, Chen, Steve, Hay, Debbie L, Lutz, Thomas A, Parkes, David G   +4 more
core   +1 more source